...in wholesale acquisition cost (WAC). The document named three branded therapies -- EpiPen , Prevacid lansoprazole...
...over five years. EpiPen's WAC rose 205% over the same time period, Humira's 114% and Prevacid's...
...national attention. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) markets Prevacid, and AbbVie Inc. (NASDAQ:ABBV) markets Humira. Becky Simon EpiPen Humira Prevacid AbbVie...

...Infectious disease INDICATION: Tuberculosis In vitro and mouse studies suggest lansoprazole analogs could help treat TB...
...FDA-approved drugs in a human cell-based assay of M. tuberculosis infection identified lansoprazole and a lansoprazole...
...Prevacid lansoprazole, a proton pump inhibitor, to treat gastroesophageal reflux disease (GERD). Takeda also has Prevacid...

...Takeda launched Takelda aspirin/lansoprazole fixed-dose combination tablets in Japan to reduce the risk of thrombosis and...
...with a history of gastric ulcer or duodenal ulcer. The tablets combine 15 mg Takepron lansoprazole...

...once-daily 20 mg oral TAK-438 met the primary endpoint of non-inferiority to once-daily 30 mg lansoprazole...
...95.5%, p<0.0001 for non-inferiority). Additionally, a post hoc analysis showed that TAK-438 was superior to lansoprazole...
...Takeda markets lansoprazole, a benzimidazole proton pump inhibitor (PPI), as Takepron in Japan and as Prevacid...

...TAK-438 as maintenance treatment each met the primary endpoint of non-inferiority to once-daily 15 mg lansoprazole...
...both). Additionally, a post hoc analysis showed that both doses of TAK-438 were superior to lansoprazole...
...Takeda markets lansoprazole, a benzimidazole proton pump inhibitor (PPI), as Takepron in Japan and as Prevacid...

...20 mg oral TAK-438 each met the primary endpoint of non-inferiority to once-daily 15 mg lansoprazole...
...week 24 was non-significantly lower in both the low- and high-dose TAK-438 arms compared to lansoprazole...
...Takeda markets lansoprazole, a benzimidazole proton pump inhibitor (PPI), as Takepron in Japan and as Prevacid...

...20 mg oral TAK-438 each met the primary endpoint of non-inferiority to once-daily 15 mg lansoprazole...
...and high-dose TAK-438 developed hemorrhagic lesion in the stomach or duodenum through week 24 vs. lansoprazole...
...Takeda markets lansoprazole, a benzimidazole proton pump inhibitor (PPI), as Takepron in Japan and as Prevacid...

...and clarithromycin for 1 week met the primary endpoint of non-inferiority to twice-daily 30 mg lansoprazole...
...treatment (92.6% vs. 75.9%, p<0.0001 for non-inferiority). Additionally, the TAK-438 regimen was superior to the lansoprazole...
...Takeda markets lansoprazole, a benzimidazole proton pump inhibitor (PPI), as Takepron in Japan and as Prevacid...

...regulatory submissions in other countries. Once-daily TAK-438 met the primary endpoint of non-inferiority to once-daily lansoprazole...
...trial, twice-daily TAK-438 plus amoxicillin and clarithromycin met the primary endpoint of non-inferiority to twice-daily lansoprazole...
...Takeda markets lansoprazole, a benzimidazole proton pump inhibitor (PPI), as Takepron in Japan and as Prevacid...

...Takeda said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA for Takelda lansoprazole/aspirin...
...who have a history of gastric and duodenal ulcer. Specifically, the fixed-dose combination of Takeda's lansoprazole...
...Takeda markets lansoprazole, a benzimidazole proton pump inhibitor (PPI), as Takepron in Japan and as Prevacid...